Compare Crispr Therapeutics AG (CRSP) vs Ishares Msci Spain ETF (EWP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ishares Msci Spain ETF — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Ishares Msci Spain ETF trades at $59.3. The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | EWP | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $60.28 |
52-Week Low | $44.34 | $43.48 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EWP is trading at $58.94, down 0.86% over the past 24 hours. The technical outlook is bullish, with moving averages signaling strength, while oscillators remain neutral. A dividend of $0.92 is scheduled for payment on June 18, 2026. Recent news highlights European market dynamics, including ECB rate hikes and regional economic performance, which may influence this US-listed stock's sentiment.
The stock's outlook is supported by bullish technical signals, but fundamental data is unavailable, limiting valuation assessment. Key risks include reliance on European economic conditions and potential volatility from monetary policy shifts. Investor sentiment appears mixed, with technical strength offset by a lack of recent fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →
